Licensing status

Publication and contact information


Using innate immune markers to detect early stage tumor recurrence

Mouse studies suggest markers of the innate immune response could help detect early tumor recurrence. In a mouse melanoma model in which T cell therapy was used to eradicate tumors, cytokine analysis of skin samples showed Il-6 and Vegf were elevated specifically at the time when latent tumor cells initiated tumor recurrence but not prior to recurrence or after the formation of larger tumors. In mice with different primary tumors, VEGF treatment induced early recurrence of tumors from latent tumor cells that had not yet acquired resistance, and these recurrent tumors were sensitive to therapy. Next steps include developing a blood or urine test to detect early immune markers of recurrence.

SciBX 6(48); doi:10.1038/scibx.2013.1411
Published online Dec. 19, 2013

Patented; available for licensing

Kottke, T. et al. Nat. Med.;
published online Nov. 17, 2013;
Contact: Richard Vile, Mayo Clinic, Rochester, Minn.